ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,071.63
0.02%
US Tech 100
16,882.80
-0.71%
Dow Jones
38,460.92
-0.11%
Brent Oil
87.22
-0.39%
Bitcoin
64,007.48
-3.62%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Geron Corp (GERN) Quote

Geron Corp

Geron Corp (GERN)

NASDAQ
3.58
0.08
(2.29%)
At close: April 24 4:00PM
Delayed by 15 minutes
3.53
0.03
( 0.86% )
After Hours: 6:45PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.53
Bid
3.52
Ask
3.58
Volume
6,956,175
3.51 Day's Range 3.709
1.64 52 Week Range 4.05
Market Cap
1.949B
Previous Close
3.50
Open
3.53
Last Trade
30
@
3.58
Last Trade Time
19:05:14
Financial Volume
$ 25,210,210
VWAP
3.6241
Average Volume (3m)
13,092,886
Shares Outstanding
546,059,309
Dividend Yield
-
PE Ratio
-10.59
Earnings Per Share (EPS)
-0.34
Revenue
237k
Net Profit
-184.13M

About Geron Corp

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.geron.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Geron Corp is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GERN. The last closing price for Geron was $3.50. Over the last year, Geron shares have traded in a share price range of $ 1.64 to $ 4.05.

Geron currently has 546,059,309 shares outstanding. The market capitalization of Geron is $1.95 billion. Geron has a price to earnings ratio (PE ratio) of -10.59.

Geron (GERN) Options Flow Summary

GERN Options Flow

Overall Flow

Bullish

Net Premium

46k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

GERN Latest News

More News

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of...

April 18 2024
Business Wire

Geron to Participate at Upcoming Investor Conferences in April

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to...

April 03 2024
Business Wire

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a...

March 19 2024
Business Wire

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

FDA Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat based on results from the IMerge Phase 3 clinical trial There are significant...

March 14 2024
Business Wire

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical...

February 28 2024
Business Wire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of...

February 22 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

February 16 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-2.754820936643.633.883.4992421793.66075649CS
40.226.646525679763.314.053.05103796733.47815261CS
121.573.89162561582.034.051.64130928862.73945449CS
261.7396.11111111111.84.051.6489759732.50545573CS
520.8431.22676579932.694.051.6473300372.58520616CS
1562.1146.8531468531.434.050.989953338072.30790783CS
2601.5981.95876288661.944.050.7541171772.16173603CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AIREreAlpha Tech Corporation
$ 1.70
(46.55%)
6.07M
CDTXCidara Therapeutics Inc
$ 17.50
(42.39%)
247.82k
ILAGIntelligent Living Application Group Inc
$ 0.7001
(29.65%)
1.89M
THMOThermoGenesis Holdings Inc
$ 0.80
(23.08%)
1.48k
NUWENewellis Inc
$ 0.307
(21.78%)
1.85M
FBLGraniteShares ETF Trust GraniteShares
$ 18.50
(-30.89%)
1.62M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3099
(-27.13%)
8.22M
CETXCemtrex Inc
$ 1.75
(-18.98%)
6.17k
METAMeta Platforms Inc
$ 417.44
(-15.41%)
12.2M
NTRBNutriband Inc
$ 3.4001
(-11.69%)
155
METAMeta Platforms Inc
$ 417.02
(-15.50%)
12.2M
SQQQProShares UltraPro Short QQQ
$ 12.1901
(3.22%)
11.88M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.3099
(-27.13%)
8.22M
FFIEFaraday Future Intelligent Electric Inc
$ 0.049
(-1.80%)
6.46M
AIREreAlpha Tech Corporation
$ 1.70
(46.55%)
6.07M

GERN Discussion

View Posts
Spike5 Spike5 1 day ago
Wow what a beating . Back in 2’s tomorrow
👍️0
Spike5 Spike5 1 day ago
Your all smart for not saying anything about this disgrace …. What 40 days away from supposed FDA approval and it is doing the same thing it did last time it was in mid 30’s . The powers to be know something!
👍️0
Spike5 Spike5 5 days ago
Wow what a disgusting company .. there is a reason why people are afraid of this
👍️0
Spike5 Spike5 1 week ago
I can’t believe it is doing the same thing it did last time it went into the mid 3’s… it went back to the low 170’s …… oh that’s right no earth shattering news left !
👍️0
Spike5 Spike5 1 week ago
Well you are getting to see the weakness of gern … everyone is going to take all of their money out of this because they are afraid of the future of this company .i said this week was going to be very important if it is able to go up it may have been a different story .
👍️0
Monksdream Monksdream 2 weeks ago
GERN has been public going back to the prior century
I should paste a very long term chart instead of a one year
New 52 hi
👍️0
JCDTrent JCDTrent 2 weeks ago
went from 3.30 to 3.60 this week...good week!
👍️0
Spike5 Spike5 2 weeks ago
Next week will be a big week … it will prove it’s worth
👍️0
JCDTrent JCDTrent 2 weeks ago
perfect "cup and handle" (stock chart buy signal) seen in the one year stock chart view for Geron Corp? Very bullish on this stock...load up boys and girls and hang on!
👍️ 2
attilathehunt attilathehunt 2 weeks ago
Looks like it happen today!!
👍️ 1
learningcurve2020 learningcurve2020 2 weeks ago
Looking good. Nice CEO chat yesterday.

"Very clear with their comfort level in managing cytopenias..."

Medical Affairs / Commercial organization in place.

If OS hits in MF it'll be transformational. IA 1/2 of 2025.

Cash good into 2026







👍️0
attilathehunt attilathehunt 2 weeks ago
We haven't been this high since June of last year. Over 10 months ago...I believe we reach a new 52 week high (3.74) by tomorrow.
👍️0
big bambino big bambino 2 weeks ago
Just 13 cents off a year high. Not hearing to much bashing now. Somebody has heard something
👍️0
attilathehunt attilathehunt 3 weeks ago
LOL!!!

So, by your reckoning, if you are so smart then why are you still here?

👍️ 1
Spike5 Spike5 3 weeks ago
Oh bullshit … this close to fda approval this should be climbing everyday the only problem is no one has enough confidence in what the approval outcome is going to be … especially the powers to be !
👍️0
attilathehunt attilathehunt 3 weeks ago
Dont expect much movement until FDA approval in June...then expect buyout within 90 days of approval.

Target $6 to $8
👍️ 2
Spike5 Spike5 3 weeks ago
Oh ya going up two days in a row would just be too much to ask for . So manipulated !
👍️0
Spike5 Spike5 3 weeks ago
Oh ok no news so down it goes this will be back under 2 in less than a month … joke !
👍️0
Spike5 Spike5 4 weeks ago
What a surprise no big ground shaking news and it’s down ….cant beat a manipulated stock
👍️0
Spike5 Spike5 4 weeks ago
I have never seen a company that needs to have earth shattering news every day yo go up or it goes down … criminal!
👍️0
DNORWOOD DNORWOOD 4 weeks ago
It’s going back below 3 looking to buy options at the right price like everyone else. Hard getting the right price. Cheers s
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
So much for seeing how it plays out. LOL.
👍️0
DNORWOOD DNORWOOD 4 weeks ago
Get ready. This is going to turn and fall. It’s over bought and the approval even if it goes thru which it will not. Will do nothing for the value of this company. Cheers.
👍️0
DNORWOOD DNORWOOD 1 month ago
I hear you. Let’s see how it plays out. Happy trading and good luck.
👍️0
learningcurve2020 learningcurve2020 1 month ago
12 to 2 tells me they've got side effects under control. Can you imagine if Imetelstat can target telomerase in most all cancers to simply inhibit the proliferation of malignant stem and progenitor cells, while in combo with other therapies! It'd be a game changer.
👍️0
DNORWOOD DNORWOOD 1 month ago
I hear you. Just don’t like all the side effects. I’m not sure it will get the final ok. Cheers.
👍️0
learningcurve2020 learningcurve2020 1 month ago
It's far too important a therapy to shelve. They have any side effects under control. For any serious therapy side effects are almost necessary, unfortunately.
👍️0
DNORWOOD DNORWOOD 1 month ago
They are not going to be approved. There is too much risk and side effects. More bad news to come.
👍️0
Spike5 Spike5 1 month ago
There won’t be anything keeping this up … everyone will take anything gains they have and run
👍️0
learningcurve2020 learningcurve2020 1 month ago
If any bad news about trials comes out shareholders will be in bad shape, no matter. Just as long as the street thinks a buyout could be in the works the price should hold up well. But this is Geron we're talking about so, I give you that.
👍️0
DNORWOOD DNORWOOD 1 month ago
OMG the ignorance of this company releasing 42 million in shares. This is so bad. The price will be pushed down every time the company sells. It any bad news about trails come out we are in real bad shape. It’s a bloodbath. Cheers
👍️0
learningcurve2020 learningcurve2020 1 month ago
Nah. Maybe to $3 for a little bit. This is exactly what's to be expected upon imminent approval. I have no issues with a raise like this. Plus Geron's now a takeover target so the cash will be reflected in the purchase price.

>>The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million. Geron currently intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and current and noncurrent marketable securities, to fund the potential commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU, subject to receipt of regulatory approvals, as well as continued development and potential regulatory submissions for imetelstat in relapsed/refractory myelofibrosis. Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes.

👍️ 1
DNORWOOD DNORWOOD 1 month ago
More shares being issued. Dilution of the shares. This is bad. Wait and see. Down she goes. Getting out here.
👍️ 1
big bambino big bambino 1 month ago
If that be the case, then why are so many capitalist groups are picking up the new shares and warrants?
👍️0
DNORWOOD DNORWOOD 1 month ago
Going down back to 2 dollars. They make no money. Cheers.
👍️0
big bambino big bambino 1 month ago
Not really, I'm still way up, with the decision from FDA still comin, I expect a great return. Thanks again
👍️ 1
Spike5 Spike5 1 month ago
Your welcome big bambino …. Pretty short lived though isn’t it ? 1 day!!
👍️0
attilathehunt attilathehunt 1 month ago
STAT News' Adam Feuerstein Publishes "I Was Wrong About Geron's Blood Cancer Drug. Now, Is It A Takeover Target?"; Shares See Volume
BENZINGA 9:08 AM ET 3/18/2024
Symbol Last Price Change
GERN 3.205up -0.155 (-4.6131%)
QUOTES AS OF 09:49:54 AM ET 03/18/2024

https://www.statnews.com/2024/03/18/geron-blood-cancer-drug-takeover-target/

I was wrong about Geron(GERN). For years, I've believed -- and declared publicly -- that Geron's(GERN) effort to develop a blood cancer drug called imetelstat would end in disappointment. The drug was never getting approved, I said.

On Thursday, a group of outside experts convened by the Food and Drug Administration voted 12-2 in imetelstat's favor, concluding the drug's benefits outweighed its risks for the treatment of patients with myelodysplastic syndrome. The strong endorsement makes an FDA approval highly likely. The decision is expected on or before June 16.
👍️ 2
Zardiw Zardiw 1 month ago
$GERN Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
big bambino big bambino 1 month ago
Spike, I want to thank you for your persistent bashing of Gern. As it dipped and you bashed, even when the numbers showed it's path, I continued to add.
👍️ 3
learningcurve2020 learningcurve2020 1 month ago
Should be a $5b market cap. Suspect this is a game changing therapy just as long as the side effects can be controlled.
👍️ 2
learningcurve2020 learningcurve2020 1 month ago
Yes!!!
👍️0
Awl416 Awl416 1 month ago
Just opened
👍️0
big bambino big bambino 1 month ago
tomorrow should be FUN 😁
👍️ 1
attilathehunt attilathehunt 1 month ago
Vote 12 - 2 in favor Benefit outweigh risk.
👍️0
attilathehunt attilathehunt 1 month ago
Listening to this, I believe the FDA will approve.
👍️0
attilathehunt attilathehunt 1 month ago
FDA ODAC Live meeting...
👍️0
Stumblebum Stumblebum 1 month ago
FDA news pending ….going way up or down this morning….one way or the other …..major drug in question
👍️0
Awl416 Awl416 1 month ago
T1 halt….
👍️0
Spike5 Spike5 1 month ago
Wow is this puking ! Unbelievable
👍️0

Your Recent History

NASDAQ
GERN
Geron
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved